Waters Corp. closed 32.12% below its 52-week high of $423.56, which the company achieved on January 30th.

In this article, you’ll find some of the top content that was published on LCGC this week, including details on the recent merger between Waters Corporation and BD Biosciences.

Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the ...

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders ...

A Connecticut-based shipping company pleaded guilty to pollution charges after crew members on one of its ships deliberately ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, ...

Waters and BD will merge biosciences and diagnostics in a $17.5B deal via Reverse Morris Trust, creating a life sciences ...

Fintel reports that on July 15, 2025, Wells Fargo downgraded their outlook for Waters (NYSE:WAT) from Overweight to ...

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

This was the stock's third consecutive day of losses.

A deal for Becton Dickinson’s biosciences and diagnostic solutions unit puts Waters Corp. in a greater position to compete ...

Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.